Eisai Limited has expanded the footprint of its Canadian Headquarters in Mississauga, Ontario.
The newly expanded headquarters reflects Eisai's continued investment in Ontario and strengthens its ability to deliver innovative care to patients across the country.
"Our growing Canadian footprint reflects our commitment to meeting the needs of patients in Canada," said Patrick Forsythe, Vice President and General Manager, Eisai Limited. "We are proud to have contributed to Ontario's life sciences ecosystem for the past 14 years, and Eisai's expansion deepens our impact as we continue to grow." Guided by our human health care (hhc) mission we strive to support all Canadians by creating solutions in areas where significant medical challenges and treatment gaps persist.
Eisai holds a strong history of continued investment in research and development and is focused on pursuing a world free from cancer, Alzheimer's disease and other neurodegenerative conditions. Driven by an ethos to improve patients' lives, Eisai has attracted a Canadian workforce that leads with passion and a connection to the patients we serve.
With this expansion, Eisai's Canada site has grown to over 100 employees representing a 246% increase since 2020, reaffirming its commitment to advancing innovative solutions for patients and contributing meaningfully to Canada's health care and life sciences future.
"In Canada, we have been on a strong growth trajectory since establishing our presence in 2011," said Tatsuyuki Yasuno, Chairman & CEO, Eisai Inc., President, Americas Region. "This expansion allows us to continue recruiting and retaining top talent, while continuing to reinvest more than 9% of our revenues annually into research."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!